Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Department of Neurological Surgery, University of California, San Francisco, CA, USA.
Ann Nucl Med. 2024 Nov;38(11):865-876. doi: 10.1007/s12149-024-01978-6. Epub 2024 Sep 17.
The gastrin-releasing peptide receptor (GRPr) has gained recognition as a promising target for both diagnostic and therapeutic applications in a variety of human cancers. This study aims to explore the primary tumor detection capabilities of [Ga] Ga-GRPr PET imaging, specifically in newly diagnosed intra-prostatic prostate cancer lesions (PCa). Following PRISMA-DTA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies) guidelines, a systematic literature search was conducted using the Medline, Embase, Scopus, and Web of Science databases. Data regarding patient characteristics and imaging procedure details-including the type of radiotracer used, administered activity, image acquisition time, scanner modality, criteria, and detection rate of index test-were extracted from the included studies. The pooled patient-and lesion-based detection rates, along with their corresponding 95% confidence intervals (CI), were calculated using a random effects model. The final analysis included 9 studies involving 291 patients and 350 intra-prostatic lesions with [Ga] Ga-GRPr PET imaging in primary PCa. In per-patient-based analysis of [Ga] Ga-GRPr PET imaging, the pooled detection rates of overall and patients with Gleason score ≥ 7 were 87.09% (95% CI 74.98-93.82) and 89.01% (95% CI 68.17-96.84), respectively. In per-lesion-based analysis, the pooled detection rate [Ga] Ga-GRPr PET imaging was 78.54% (95% CI 69.8-85.29). The pooled detection rate mpMRI (multiparametric magnetic resonance imaging) in patient-based analysis was 91.85% (95% CI 80.12-96.92). The difference between the detection rates of the mpMRI and [Ga] Ga-GRPr PET imaging was not statistically significant (OR 0.90, 95% CI 0.23-3.51). Our findings suggest that [Ga] Ga-GRPr PET imaging has the potential as a diagnostic target for primary PCa. Future research is needed to determine the effectiveness of [Ga] Ga-GRPr PET in delivering additional imaging data and guiding therapeutic decisions.
胃泌素释放肽受体（GRPr）已被认可为各种人类癌症的诊断和治疗应用的有前途的靶标。本研究旨在探索 [Ga] Ga-GRPr PET 成像在新诊断的前列腺内前列腺癌病变（PCa）中的原发性肿瘤检测能力。根据 PRISMA-DTA（诊断测试准确性研究的系统评价和荟萃分析的首选报告项目）指南，使用 Medline、Embase、Scopus 和 Web of Science 数据库进行了系统文献检索。从纳入的研究中提取了患者特征和成像程序细节的数据，包括使用的放射性示踪剂类型、给予的活度、图像采集时间、扫描仪模式、标准和指数测试的检测率。使用随机效应模型计算了基于患者和病变的汇总检测率及其相应的 95%置信区间（CI）。最终分析包括 9 项研究，涉及 291 名患者和 350 例原发性 PCa 中的前列腺内病变的 [Ga] Ga-GRPr PET 成像。在基于患者的 [Ga] Ga-GRPr PET 成像分析中，总体和 Gleason 评分≥7 患者的汇总检测率分别为 87.09%（95%CI 74.98-93.82）和 89.01%（95%CI 68.17-96.84）。在基于病变的分析中，[Ga] Ga-GRPr PET 成像的汇总检测率为 78.54%（95%CI 69.8-85.29）。在基于患者的分析中，mpMRI（多参数磁共振成像）的汇总检测率为 91.85%（95%CI 80.12-96.92）。mpMRI 和 [Ga] Ga-GRPr PET 成像的检测率之间的差异没有统计学意义（OR 0.90，95%CI 0.23-3.51）。我们的研究结果表明，[Ga] Ga-GRPr PET 成像具有作为原发性 PCa 的诊断靶标的潜力。需要进一步的研究来确定 [Ga] Ga-GRPr PET 在提供额外的成像数据和指导治疗决策方面的有效性。
